European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.
about
Surgical resection of urological tumor metastases following medical treatmentGerman second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practice.Canadian consensus guidelines for the management of testicular germ cell cancer.Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature.Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer--a single center analysisEffectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors.Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors.Pure seminoma: a review and updateLow RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer.Prostatic relapse of an undifferentiated teratoma 24 years after orchidectomy.A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor.Current update of management of clinical stage I non seminomatous germ cell tumors of testisOptimal management of testicular cancer: from self-examination to treatment of advanced diseaseObservational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.Stage I seminoma: what should a practicing uro-oncologist do in 2009?Update on management of seminoma.A pathologist's view on the testis biopsy.Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update.Minimizing toxicity in early-stage testicular cancer treatment.Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity.The role of high-dose chemotherapy in the treatment of testicular cancer.Cisplatin resistance in germ cell tumours: models and mechanisms.Management of residual mass in nonseminomatous germ cell tumors following chemotherapy.Role of imaging in testicular cancer: current and future practice.HMGA2 expression distinguishes between different types of postpubertal testicular germ cell tumour.αvβ3 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study.Management of poor-prognosis testicular germ cell tumors.Chemotherapy intensification in patients with advanced seminoma and adverse prognostic factors.FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment.[A multi-disciplinary approach to the treatment of germ cell tumors].Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study.Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer.[Pharmacological therapy of urogenital cancer: rational routine diagnostic imaging].Markedly increased incidence and improved survival of testicular cancer in the Netherlands.Long-term cognitive function following chemotherapy in patients with testicular cancer.Utility of serum tumor markers during surveillance for stage I seminoma.First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database.Mixed testicular germ cell tumor presenting as metastatic pure choriocarcinoma involving multiple lung metastases that was effectively treated with high-dose chemotherapy.
P2860
Q27013035-6D985DB7-13C1-4135-B4D1-009527F7E45DQ33747347-6F174C8A-4560-4A17-A25B-A5759E24F9EFQ33753786-1F6E637D-B7A8-4BC5-96AC-DFC9D71C1862Q33922991-D17CEBFB-CE00-48A8-A3B7-718C016F06B6Q34022779-C29D77CE-62BB-4A35-9AD6-1353E4529FFBQ34287973-6B0236EB-A86E-4C96-9505-B58EFF6BA841Q34928941-E61B89CC-1E8F-4B6B-A271-E011237C3799Q35076383-913A2C75-B79B-45CC-B66A-567B4BC45687Q35184991-37FCB46E-2EDB-4F20-87CB-DB089CC6663AQ35219992-74B70B70-F32B-4382-AEA8-20A8A7BE63FFQ35795796-AA86838A-7628-4567-B284-A19CE82E4E05Q36049048-DDD6C719-E607-407D-9622-7D412405EE68Q36084071-92375EBD-7FEE-4773-BE16-17476DE4123EQ37283572-DB6C7E01-D9F5-48B8-A474-FAB98614E628Q37478015-412E9429-DD6A-4E63-9734-F692A000487EQ37488435-B19D3294-B359-45A7-B0C7-722F5E55A641Q37763853-A646A373-BD1C-4D5B-8700-25446F847481Q37905873-DA2324E9-2F4A-4575-8E42-449740A9050FQ37905875-D47A129A-920B-4288-A1B3-9EF4CDEB53FFQ37982443-76A0FC6E-5129-408B-AC87-0860556AAB95Q38036587-F92318B2-F8BC-41D2-B5FC-DB73294C037FQ38160470-DEB6CE57-8D1D-474D-A185-F585B939374AQ38302534-5D49A369-A695-4D0C-A863-B86CD821ADA6Q38509309-C2748CCF-A4C9-4FC5-8EEF-309B357C8055Q38575307-BD23DACA-D95C-4C86-AC94-BEA19D26CD6FQ39514230-DFAEAC76-A474-4A36-BC2B-676CC9CD284BQ39649778-07FCCF25-C20C-4C6E-91DB-9E0607BBC5E2Q40810851-50528942-1488-40AF-BF9E-097224F2B001Q41585249-8FA9BE10-FFB1-4E5A-A6D9-0C9F7987D791Q42433649-DDA900CE-27FB-4D5C-8FDC-94A61DF7F131Q42861831-F627F924-6792-46F8-85C7-6A3A8171D779Q43016615-706623BB-563F-4002-A26A-27E5328BE6B3Q43130009-A9AFCA49-27D9-4EF3-B3F3-E76BE39F565BQ43223621-6D333F06-A62A-459D-88FB-1D54D24AC658Q44017338-155433EA-E631-4DE5-80D1-1E29F0605A22Q46055438-45C96725-CC7D-46F0-A0F1-6D30D8A8B146Q46128358-35BBBAFC-B70E-4DD7-9FD8-EC444A842DEEQ47880437-44427A4B-5222-4ABD-B896-429458D26FAFQ48456639-FF27337C-B24A-41F3-BAD8-12CF7B9C95FCQ49775506-A2F7AEAD-1C76-48A6-A4E0-2813C4CB1423
P2860
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
European consensus conference ...... ensus Group (EGCCCG): part II.
@en
European consensus conference ...... rm Cell Cancer Consensus Group
@nl
type
label
European consensus conference ...... ensus Group (EGCCCG): part II.
@en
European consensus conference ...... rm Cell Cancer Consensus Group
@nl
prefLabel
European consensus conference ...... ensus Group (EGCCCG): part II.
@en
European consensus conference ...... rm Cell Cancer Consensus Group
@nl
P2093
P50
P1433
P1476
European consensus conference ...... ensus Group (EGCCCG): part II.
@en
P2093
Alan Horwich
Annette Dieing
Arthur Gerl
Aslam Sohaib
Aude Flechon
Axel Heidenreich
Carsten Bokemeyer
Christian Kollmannsberger
Christian Wittekind
Christoph Clemm
P304
P356
10.1016/J.EURURO.2007.12.025
P407
P50
P577
2007-12-26T00:00:00Z